摘要
目的:研究肿瘤坏死因子相关凋亡诱导配体(TRAIL)启动子区-716A/G位点单核苷酸多态性(SNP)与影响前列腺癌危险因素的关系。方法:应用聚合酶链反应-连接酶特异检测技术(PCR-LDR)分析186例前列腺癌患者TRAIL基因-716位点的多态性,比较不同基因型与前列腺癌患者诊断时的前列腺癌特异性抗原(PSA)、Gleason评分和TNM临床分期的关系。结果:TRAIL-716G(AG+GG)等位基因与PSA、Gleason评分和TNM临床分期均具有显著的相关性(adjusted OR=0.04,0.07,0.08;95%CI:0.01～0.14,0.02～0.29,0.03～0.21)。结论:TRAIL-A716G(AG+GG)等位基因可能与前列腺癌预后有关,携带TRAIL-716G(AG+GG)等位基因的前列腺癌患者可能预后较好。
Objective： To investigate the potential association between the polymorphism in promoter of TRAIL-716 genotypes and risk factors （PSA, Gleason score and TNM clinical stage） of prostate cancer. Methods： The polymorphism of TRAIL-716 sites was analyzed by polymerase chain reaction-ligase detection reaction （PCR-LDR） technique using genomic DNA isolated from peripheral blood. The association between the risk factors of prostate cancer and different genotypes was evaluated. Results：The TRAIL-716G variant allele （AG＋GG） was associated with lower PSA value of prostate cancer （adjusted OR = 0.04; 95%CI = 0.01-0. 14）. It was also noted that the TRAIL-716G variant allele was associated with lower Gleason score and earlier TNM clinical stage of prostate cancer patients （adjusted OR = 0. 07, 0.08; 95% CI = 0.02-0. 29, 0. 03-0. 21, respectively）. Conclusions： The results demonstrated that the TRAIL-716 A to G variant influenced the PSA value, Gleason score and TNM clinical stage of prostate cancer. The TRAIL-716G variant might have a protective effect in the prognosis of prostate cancer.
出处
《临床泌尿外科杂志》
北大核心
2011年第2期143-146,共4页
Journal of Clinical Urology
关键词
肿瘤坏死因子相关凋亡诱导配体
前列腺癌
启动子
tumor necrosis factor-related apoptosis inducing ligand
prostate cancer
promoter
